On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

Esketamine comes as a nasal spray that you inhale. Specifically, Spravato is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults: Spravato is a brand ...

To get FDA approval, scientists must be able to demonstrate that a new drug or treatment is safe and effective. And currently, before they can test a new therapy in humans, they must show proof ...

Esketamine does of 56 and 84 mg with comprehensive standard-of-care rapidly improved depressive symptoms in adolescents at risk for suicide.

American Behavioral Clinics (ABC) is proud to announce the launch of SPRAVATO® (esketamine) treatment at its Oak Creek clinic.